Abstract
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 293-296 |
| Number of pages | 4 |
| Journal | Best Practice and Research: Clinical Haematology |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- GVL, graft-versus-leukemia
- HCT hematopoietic cell transplantation
- HLA-matched donors
- UCB, umbilical cord blood
- bone marrow
- graft source
- haploidentical
- peripheral blood
- relapse
Fingerprint
Dive into the research topics of 'Which donor or graft source should you choose for the strongest GVL? Is there really any difference'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS